Welcome to our dedicated page for Tonix Pharmaceut news (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceut stock.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) generates a steady flow of news as a fully integrated, commercial-stage biotechnology company with both marketed products and a broad development pipeline. News coverage for Tonix often centers on its FDA-approved fibromyalgia treatment TONMYA, its acute migraine products Zembrace SymTouch and Tosymra, and updates on clinical and regulatory milestones across central nervous system, immunology, rare disease and infectious disease programs.
Investors following TNXP news can expect announcements on commercial launches, market access decisions, and distribution arrangements for TONMYA, as well as prescription trends and formulary placements for its migraine therapies. The company also regularly reports progress on TNX-102 SL in indications such as acute stress-related conditions and major depressive disorder, including IND clearances and the design of potentially pivotal Phase 2 studies.
Tonix’s immunology and infectious disease work contributes additional news items, including collaborations with academic centers like Massachusetts General Hospital for TNX-1500 in kidney transplantation, and development plans for TNX-4800, a monoclonal antibody designed for seasonal prevention of Lyme disease. Licensing transactions, such as the acquisition of TNX-4900 for chronic neuropathic pain from Rutgers University, and government-supported projects like the DTRA-backed antiviral TNX-4200, are also common themes in company press releases.
This TNXP news page aggregates company-issued updates and related coverage so readers can quickly review developments in Tonix’s commercial operations, clinical pipeline, financing activities, and strategic collaborations. For investors and observers tracking biotech catalysts, revisiting this page provides a concise way to monitor how Tonix’s programs and capital markets actions evolve over time.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced the opening of its new 45,000 sq ft Advanced Development Center (ADC) in North Dartmouth, Massachusetts, on June 21, 2022. The facility will enhance the company's ability to manufacture clinical quality vaccines for infectious diseases such as monkeypox, smallpox, and COVID-19. The ADC includes state-of-the-art bioreactors and is designed to support U.S. pandemic preparedness. With the capability to employ 70 staff, this facility is a significant step toward accelerating vaccine development and production.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) unveiled promising data on its TNX-1500 monoclonal antibody at the 2022 American Transplant Congress. The research, conducted by Massachusetts General Hospital, shows that TNX-1500 effectively prevents organ transplant rejection in non-human primates, demonstrating both efficacy and safety. Tonix's CEO highlighted the need for improved treatments in this area, as no effective humanized anti-CD40L antibody exists yet. The company is actively moving into Phase 1 studies for TNX-1500 and continues its development approach across various therapeutic areas.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced an oral presentation highlighting the activity of Wnt/β-Catenin signaling pathway inhibitors against SARS-CoV-2. Presented by Dr. Tom Hobman at the Canadian Society for Virology, the research revealed that these inhibitors reduced lung infection in an animal model. The presentation included promising data on these drugs, some of which have been studied in humans or are FDA approved. Tonix aims to advance these candidates towards clinical testing, indicating a strategic focus on broad-spectrum antiviral development.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced a successful presentation of preclinical data for its vaccine TNX-801 at the 4th Symposium of the Canadian Society for Virology on June 5, 2022. The study demonstrated that all vaccinated macaques achieved sterilizing immunity against monkeypox following exposure. The data, presented by researchers from Tonix and the University of Alberta, highlights the vaccine's potential to combat rising monkeypox cases globally. TNX-801 is based on synthetic horsepox and aims to provide protection against both monkeypox and smallpox.
Tonix Pharmaceuticals (Nasdaq: TNXP) will present at the 2022 BIO International Convention scheduled for June 13-16 in San Diego, CA. The presentation is set for June 13 at 3:45 p.m. PT. Tonix focuses on developing therapeutics in areas such as central nervous system disorders and infectious diseases. Key projects include TNX-102 SL for fibromyalgia and Long COVID, TNX-1300 for cocaine intoxication, and vaccines for smallpox and COVID-19. As a clinical-stage biopharmaceutical company, Tonix's product candidates are investigational and have not yet received FDA approval.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced it has regained compliance with Nasdaq's minimum bid price requirement, having maintained a closing bid price of $1.00 or above for 10 consecutive business days as of June 1, 2022. This compliance closure means Tonix can continue its listing on The Nasdaq Capital Market. The company is actively advancing multiple clinical-stage candidates, including treatments for fibromyalgia and Long COVID, while also working on vaccines for smallpox, monkeypox, and COVID-19.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced the issuance of U.S. Patent No. 11,345,896 on May 31, 2022, by the USPTO. This patent secures synthetic horsepox virus technology crucial for its TNX-801 vaccine, aimed at combating monkeypox and smallpox. Additionally, TNX-1840 and TNX-1850 are in development targeting COVID-19 variants. The new patent enhances Tonix's vaccine pipeline and provides market exclusivity until 2037, underscoring its leadership in synthetic biology and the potential for advancing innovative vaccines.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) has launched a $12.5 million share repurchase program aimed at buying back its common stock from the open market and through private negotiations, based on market conditions. Funding will come from available cash. The program may be adjusted or halted depending on market evaluations and is expected to enhance shareholder value by reducing the number of outstanding shares. This announcement follows the recent advancements in Tonix's clinical-stage pipeline, specifically in CNS and infectious diseases.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced two oral presentations at the 2022 American Transplant Congress taking place June 4-8, 2022, in Boston, MA. The presentations, led by faculty from Massachusetts General Hospital, focus on TNX-1500, an Fc-modified anti-CD40L monoclonal antibody aimed at preventing organ transplant rejection. Key studies include:
- Long-Term Rejection Free Renal Allograft Survival - June 5, 6:20 PM
- Prolongs Nonhuman Primate Cardiac Allograft Survival - June 7, 5:50 PM
Details are available on the company's website.
Tonix Pharmaceuticals announced a license agreement with the University of Alberta to develop broad-spectrum antiviral drugs targeting SARS-CoV-2 and other viruses. The collaboration focuses on Wnt/β-Catenin pathway inhibitors, which have shown promise in reducing virus replication and enhancing interferon production. Tonix's antiviral efforts align with their broader goal of pandemic preparedness. The company is also advancing multiple product candidates across its pipeline, including treatments for fibromyalgia, Long COVID, and cocaine intoxication.